{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:24:03Z","timestamp":1788452643011,"version":"build-2803163510"},"reference-count":19,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Fenofibrate, a PPAR-\u03b1 agonist, has been demonstrated to reduce the progression of diabetic retinopathy (DR) and the need for laser treatment in a FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study. However, in the subgroup of patients without pre-existing DR, there was no significant difference in the progression of DR between the fenofibrate group and the placebo group. In this study, we aim to investigate whether fenofibrate can decrease the risk of incident DR in a population-based cohort study of type 2 diabetic patients in Taiwan. Materials and Methods: A total of 32,253 type 2 diabetic patients without previous retinopathy were retrieved from 892,419 patients in 2001\u20132002. They were then divided into two groups based on whether they were exposed to fenofibrate or not. The patients were followed until a diagnosis of diabetic retinopathy was made or until the year 2008. Results: With a follow-up period of 6.8 \u00b1 1.5 years and 5.4 \u00b1 2.6 years for 2500 fenofibrate users and 29,753 non-users, respectively, the Cox proportional hazard regression analysis revealed that the hazard ratio (HR) of new onset retinopathy was 0.57 (95% CI 0.57\u20130.62, p &lt; 0.001). After adjusting for hypertension; the Charlson comorbidity index (CCI); and medications such as angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), anticoagulants, gemfibrozil, statins, and hypoglycemic agents, the adjusted HR was 0.75 (95% CI 0.68\u20130.82, p &lt; 0.001). The need for laser treatment has an HR and adjusted HR of 0.59 (95% CI 0.49\u20130.71, p &lt; 0.001) and 0.67 (95% CI 0.56\u20130.81, p &lt; 0.001), respectively. Conclusion: Our study showed that the long-term and regular use of fenofibrate may decrease the risk of incident retinopathy and the need for laser treatment in type 2 diabetic patients. Since there are limitations associated with our study, further investigations are necessary to confirm such an association.<\/jats:p>","DOI":"10.3390\/medicina56080385","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T03:16:46Z","timestamp":1596424606000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan"],"prefix":"10.3390","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-4192","authenticated-orcid":false,"given":"Ying-Chieh","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorng-Tzong","family":"Horng","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan"},{"name":"Department of Computer Science and Information Engineering, National Central University, Chungli 32001, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan"},{"name":"Department of Endocrinology and Metabolism, Tungs\u2019 Taichung MetroHarbor Hospital, Taichung 43503, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ophtha.2008.10.003","article-title":"Prevalence of diabetic retinopathy in rural China: The Handan Eye Study","volume":"116","author":"Wang","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","article-title":"Diabetic retinopathy","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group, Nathan, D.M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L., and Siebert, C. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med., 329, 977\u2013986.","DOI":"10.1056\/NEJM199309303291401"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"ref_10","unstructured":"NHIRD (2013, June 09). Introduction to the National Health Insurance Research Database (NHIRD), Taiwan. Available online: http:\/\/nhird.nhri.org.tw\/en\/index.htm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00125-009-1457-x","article-title":"Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: A randomised controlled trial","volume":"52","author":"Beulens","year":"2009","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00125-011-2089-5","article-title":"Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation","volume":"54","author":"Villarroel","year":"2011","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.exer.2007.01.009","article-title":"Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway","volume":"84","author":"Kim","year":"2007","journal-title":"Exp. Eye Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1167\/iovs.11-7282","article-title":"Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: Functional implications in retinal permeability","volume":"52","author":"Trudeau","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/db11-0413","article-title":"Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models","volume":"62","author":"Chen","year":"2013","journal-title":"Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.eye.6701668","article-title":"Dyslipidaemia and microvascular disease in the retina","volume":"19","author":"Leung","year":"2005","journal-title":"Eye (Lond)"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:53:16Z","timestamp":1760176396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["medicina56080385"],"URL":"https:\/\/doi.org\/10.3390\/medicina56080385","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}